CD19 and acute lymphoblastic leukemia: A study evaluating the efficacy and safety of CD19-targeted CAR-T cell therapy in 48 patients with R/R B-ALL with CNS involvement indicated a remission rate of 85.4% in the CNS, with a median event-free survival (EFS) of 8.7 months and a median OS of 16.0 months during a median follow-up of 11.5 months.